Wei Zhong
Company: Wayshine Biopharm
Job title: CEO
Seminars:
Exploring WSD0628: A CNS-Penetrable ATM Inhibitor for Radiosensitization in Recurrent Brain Cancer 2:50 pm
Investigating WSD0628's pharmacokinetic properties to determine its brain penetration efficacy and systemic exposure Evaluating the synergistic effects of WSD0628 combined with radiation therapy in recurrent brain cancer models, focusing on therapeutic outcomes and safety Assessing the impact on survival in preclinical intracranial models, including glioblastoma, DIPG, and brain metastases, to understand potential clinical benefitsRead more
day: Day One